Research programme: obesity therapy - BEXEL Pharmaceuticals

Drug Profile

Research programme: obesity therapy - BEXEL Pharmaceuticals

Alternative Names: BLX-1028; BLX-2002

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator BEXEL Pharmaceuticals
  • Class Amino acids; Dipeptides; Small molecules
  • Mechanism of Action Nitric oxide synthase type II inhibitors; Tumour necrosis factor alpha inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Obesity

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Obesity in USA (PO)
  • 05 Sep 2007 Preclinical development is ongoing
  • 21 Nov 2005 Data presented at the 2005 Annual Meeting of the North American Association for the Study of Obesity (NAASO-2005) have been added to the Obesity pharmacodynamics section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top